Full-resolution static daily chart · Nasdaq: VSTMThe referral applies only when the chart is clicked.
Merlintrader Stock HubCommercial oncology · RAS/MAPKUpdated August 7, 2026
Verastem Oncology ($VSTM) Stock Hub: Q2 2026 launch, VS-7375, RAMP 301 and the next catalysts
The complete VSTM research hub after the August 6 earnings update: AVMAPKI FAKZYNJA launch economics, the confirmatory RAMP 301 trial, VS-7375 clinical evidence, TARGET-D expansion, pancreatic-cancer optionality, cash runway, revenue-linked financing, dilution, ownership and every visible catalyst through mid-2027.
Next clinical catalystOctober 2026
Verastem guides to updated VS-7375 clinical data in October. Before that, the expected August 28 closing of a $50 million Oberland revenue-note tranche is the immediate financing checkpoint. The later value-defining event is RAMP 301 topline in mid-2027.
Last full close$5.91August 6, 2026; not a live quote
Basic equity value≈ $535M90.563M shares × $5.91
Q2 product revenue$25.1M+34% sequentially from Q1
Q2 total revenue$40.1MIncludes a $15M COPIKTRA milestone
Cash + investments$136.4MJune 30, 2026
Pro forma liquidity$201.4MIncluding $15M July receipt and expected $50M financing
Shares + PF warrants≈ 100.29M90.56M common + 9.73M pre-funded warrants
Next data windowOctoberUpdated VS-7375 clinical data
Executive summary: a real oncology launch now funds a much larger clinical bet
Verastem has crossed from pre-commercial biotech into a hybrid launch-and-pipeline story. AVMAPKI FAKZYNJA generated $25.1 million of Q2 product revenue, up 34% sequentially, while the company is simultaneously expanding VS-7375 into three Phase 2 tumor programs and maintaining a global confirmatory Phase 3 trial.
The near-term bull argument is no longer based only on clinical promise. The approved LGSOC franchise has produced five quarters of progressively larger revenue since its May 2025 launch, with Q2 2026 product sales above the $18.7 million recorded in Q1. Management says the franchise can become self-sustaining by year-end 2026. If quarterly worldwide product sales reach at least $40 million, the company can also access an optional $25 million Oberland tranche before May 15, 2027.
The counterweight is the cost of building the next franchise. Q2 R&D expense rose 67% year over year to $41.3 million, SG&A reached $27.4 million and first-half operating cash use was $96.0 million. The 10-Q states that substantial doubt exists about the company’s ability to continue as a going concern for the next twelve months under the accounting standard, even though management’s operating plan—product revenue plus financing access—extends the stated runway into the second half of 2027.
What may be mispriced
The market may be undervaluing the coexistence of a measurable commercial launch, a confirmatory Phase 3 program and an externally licensed KRAS G12D asset with activity across pancreatic, lung and colorectal settings. October data can narrow the probability range around VS-7375 before the pivotal LGSOC readout.
What is already priced in
At roughly $535 million of basic equity value, VSTM is not a cash-shell valuation. Investors are already paying for continued launch growth and some pipeline value. A commercial plateau, data that fail to convert biomarkers into radiographic responses, or a financing delay can compress that premium quickly.
What proves the thesis
Quarterly product revenue moving toward the $40 million financing threshold; October VS-7375 data showing objective responses and durability at the 900 mg dose; completion of all TARGET-D Phase 2 enrollment by year-end; and RAMP 301 confirming clinical benefit in mid-2027.
What kills the thesis
A sharp launch slowdown, deterioration in net pricing or refill behavior, unexpected toxicity at scale, Phase 2 recruitment slippage, or a RAMP 301 result that does not confirm the benefit required to support accelerated approval.
Research posture: watchlist / wait for proof. Evidence confidence is high for reported financials and scheduled company guidance, but underwriting remains preliminary because there is no post-earnings consensus model, no independently verified 2026–2027 revenue forecast and no probability-weighted rNPV robust enough to support a target price.
Company map: one commercial franchise and two development engines
Verastem Oncology is focused on cancers driven by the RAS/MAPK pathway. Its operating model now has three distinct engines. The first is the U.S. launch of AVMAPKI FAKZYNJA for KRAS-mutated recurrent low-grade serous ovarian cancer. The second is the RAF/MEK and FAK inhibitor platform, including the confirmatory RAMP 301 trial and the RAMP 205 pancreatic-cancer combination. The third is VS-7375, a selective oral KRAS G12D inhibitor licensed from GenFleet for territories outside mainland China, Hong Kong, Macau and Taiwan.
| Asset / program | Setting | Status at cut-off | Value question |
|---|---|---|---|
| AVMAPKI FAKZYNJA avutometinib + defactinib | KRAS-mutated recurrent LGSOC after prior systemic therapy | FDA accelerated approval; U.S. commercial launch | Can the launch scale fast enough to cover franchise costs and support the broader pipeline? |
| RAMP 301 | Recurrent LGSOC across KRAS status | Global confirmatory Phase 3; fully enrolled December 2025 | Can randomized data confirm benefit and broaden the label to KRAS wild-type disease? |
| VS-7375 / GFH375 | KRAS G12D solid tumors | Phase 1 dose work plus three Phase 2 TARGET-D studies | Does early pharmacology translate into durable response rates competitive with a fast-moving field? |
| RAMP 205 | First-line metastatic pancreatic cancer | Phase 1b/2 triplet with gemcitabine/nab-paclitaxel | Can a 52% early response signal in 29 patients survive longer follow-up and controlled testing? |
The company’s strategic transition matters to valuation. A pure clinical-stage company is assessed mainly through probability-adjusted pipeline value and cash runway. Verastem must now also be assessed on gross-to-net price, refill persistence, account penetration, inventory, receivables, cost of sales and the operating leverage of a specialist commercial organization.
Mechanistic logic without promotional shortcuts
Avutometinib is designed to inhibit RAF and MEK signaling; defactinib inhibits focal adhesion kinase, or FAK. The combination aims to suppress MAPK signaling and adaptive resistance. VS-7375 targets KRAS G12D in both the active and inactive conformations. These descriptions explain why the programs may work. They do not establish clinical superiority, and the Stock Hub therefore separates mechanism, observed data and management interpretation.
The launch is accelerating, but revenue quality matters more than one headline quarter
AVMAPKI FAKZYNJA received FDA accelerated approval on May 8, 2025 for adults with KRAS-mutated recurrent LGSOC after prior systemic therapy. Product revenue has risen in every full quarter disclosed since launch. Q2 2026 product revenue reached $25.1 million, compared with $18.7 million in Q1, a sequential increase of approximately 34%.
| Quarter | Product revenue | Sequential change | Interpretation |
|---|---|---|---|
| Q2 2025 | $2.1M | Launch quarter | Partial quarter following May approval. |
| Q3 2025 | $11.2M | +424% | First full quarter; initial account stocking and starts. |
| Q4 2025 | $17.5M | +56% | Broader adoption and repeat ordering. |
| Q1 2026 | $18.7M | +7% | Growth continued but slowed sequentially. |
| Q2 2026 | $25.1M | +34% | Re-acceleration; strongest quarter to date. |
Cumulative product revenue since launch is approximately $74.5 million. That is meaningful commercial validation in a rare ovarian-cancer segment. It is still too early to extrapolate a stable run rate. Quarterly revenue can be affected by inventory timing, gross-to-net adjustments, new-patient starts, treatment duration, discontinuations and specialty-pharmacy ordering patterns.
Product revenue in USD millions · company-reported figures · Q2 2025 was a partial launch quarter
Editorial read: Q2 re-accelerated after a flatter Q1, but five quarters are not enough to establish a mature demand curve.
Operating leverage gate
Management says the LGSOC franchise can become self-sustaining by year-end 2026. Investors should monitor product gross profit against dedicated commercial and medical-affairs costs, not simply product revenue against total company spending.
$40 million threshold
The optional $25 million financing tranche requires worldwide product sales of at least $40 million in the preceding calendar quarter. That is a contract condition, not company revenue guidance. From Q2’s $25.1 million base, the threshold would require roughly 59% sequential growth.
Approval scope
The current label is restricted to KRAS-mutated recurrent LGSOC after prior systemic therapy. Expansion to KRAS wild-type patients depends on supportive RAMP 301 data and regulatory review; it should not be included in the base commercial population today.
Confirmatory obligation
Accelerated approval can be withdrawn or narrowed if the confirmatory trial fails to verify clinical benefit or is not completed with due diligence. RAMP 301 is therefore both a growth option and a defense of the existing franchise.
Commercial KPI stack for future quarters: product revenue, sequential growth, gross-to-net commentary, new accounts, refill persistence, treatment duration, inventory movements, receivables, cost of product sales and progress toward self-sustainability.
LGSOC franchise: approved evidence, durable follow-up and one confirmatory verdict
Low-grade serous ovarian cancer is a rare, biologically distinct ovarian malignancy that often affects younger patients and can be relatively resistant to conventional chemotherapy. The RAS/MAPK pathway is central to the disease, but KRAS mutation status does not capture every tumor in which pathway suppression may be relevant.
What the FDA approval established
The approved co-pack pairs avutometinib with defactinib for a defined KRAS-mutated recurrent population. FDA used the accelerated-approval pathway, meaning response data supported earlier access while a confirmatory trial evaluates clinical benefit. The approval is real commercial de-risking; it is not the same as a fully confirmed broad LGSOC label.
RAMP 201 and the durability layer
Verastem reported two-year follow-up from RAMP 201 in April 2026, emphasizing durable responses across KRAS-mutated and KRAS wild-type cohorts. Longer follow-up matters because duration of response is a major determinant of clinical value in an indolent but recurrent disease. However, investor attention should remain on the randomized RAMP 301 endpoint because single-arm durability cannot replace a controlled confirmatory result.
Japan cohort supports geographic optionality, not yet a registration conclusion
In July 2026, the RAMP 201J cohort reported 16 efficacy-evaluable Japanese patients at a median follow-up of 12.4 months. The confirmed objective response rate was 44% and disease-control rate was 94%; 94% experienced tumor shrinkage and 11 of 16 remained on treatment at the cut-off. The KRAS-mutant subgroup showed a 71% response rate, while the wild-type subgroup showed 22%. The sample is very small, and subgroup percentages are especially unstable.
| Program | Population | Key evidence | Limit |
|---|---|---|---|
| RAMP 201 | Recurrent LGSOC | Registration-supporting response and duration evidence; two-year follow-up reported | Single-arm interpretation and accelerated-approval framework |
| RAMP 201J | Japanese recurrent LGSOC | 44% ORR and 94% DCR in 16 efficacy-evaluable patients | Very small cohort; not a comparative trial |
| RAMP 301 | Global recurrent LGSOC, all KRAS statuses | Fully enrolled December 2025; topline guided mid-2027 | Primary endpoint remains unknown; regulatory outcome not guaranteed |
Read-through discipline: a positive RAMP 301 result can protect the current accelerated approval, support KRAS wild-type expansion and strengthen ex-U.S. filings. A negative or ambiguous result can affect all three simultaneously.
VS-7375: credible early pharmacology, but October must move the evidence beyond biomarkers
VS-7375, also known as GFH375 in GenFleet’s territories, is an oral selective KRAS G12D inhibitor designed to bind both the active and inactive forms of the target. Verastem controls development and commercialization outside mainland China, Hong Kong, Macau and Taiwan. More than 200 patients had been treated in TARGET-D101 by the Q2 update, giving the program a broader safety base than the earliest conference snapshot.
Dose selection and tolerability
At the June 12, 2026 data cut-off, monotherapy safety was described for 57 patients at 600 mg and 25 patients at 900 mg. Most treatment-related events were low-grade gastrointestinal effects that diminished after the first cycle. One grade 3 nausea event at 900 mg resolved. The company reported low rash incidence, no rash above grade 1, no clinically meaningful cytopenias or liver abnormalities and no observed cumulative toxicity at that stage.
Pharmacokinetic data showed the 900 mg dose achieving target plasma exposure with separation from 600 mg. A 1,200 mg cohort was later cleared without dose-limiting toxicities. Dose clearance is a safety milestone, not proof that the higher dose has the best therapeutic index or superior efficacy.
Pancreatic signal: important, but CA19-9 is not the endpoint
Among 14 evaluable metastatic pancreatic-cancer patients treated with 900 mg monotherapy, 13 had a greater than 50% decline in CA19-9 and all remained on treatment at the cut-off. The uniformity of the biomarker decline is encouraging. CA19-9 is not a validated substitute for confirmed objective response, progression-free survival or overall survival, and it can be influenced by biliary obstruction and other clinical factors.
Colorectal and lung expansion
The colorectal program combines VS-7375 with EGFR blockade because feedback signaling can limit KRAS inhibitor activity in CRC. The 900 mg combination dose-limiting-toxicity cohort with cetuximab cleared without overlapping toxicity. In previously treated NSCLC, the company described preliminary activity at 600 mg, with the dataset still immature. October should provide the first chance to evaluate tumor-specific response depth, confirmation, durability and dose response in a more investable form.
Regulatory signals
FDA granted Fast Track designation in first- and second-line pancreatic cancer in July 2025 and in previously treated NSCLC in June 2026. GenFleet received a China Breakthrough Therapy designation in April 2026 for previously treated KRAS G12D metastatic pancreatic cancer.
What designations do not mean
Fast Track can increase regulatory interaction and enable rolling review, while China’s designation can facilitate development. Neither establishes efficacy, guarantees an accelerated path or changes the need for adequate clinical evidence.
Erasca combination option
In July, Verastem and Erasca agreed to preclinical work combining VS-7375 with ERAS-0015. A future clinical collaboration is conditional. It is scientific optionality, not a funded trial or commercial partnership today.
October decision test
The key question is whether the 900 mg exposure and biomarker signal convert into confirmed radiographic responses with acceptable duration across PDAC, NSCLC and CRC, without a safety cost that narrows combination use.
TARGET-D program: three Phase 2 starts transform execution risk
Verastem initiated three tumor-specific Phase 2 trials within six weeks. That pace creates a broad opportunity to find the best registration path, but it also explains the rapid rise in R&D expense and the going-concern language. Enrollment quality, site activation and cohort prioritization are now central operating metrics.
| Study | First patient | Core cohorts | Near-term objective |
|---|---|---|---|
| TARGET-D101 | Ongoing Phase 1 | Dose escalation/expansion across KRAS G12D solid tumors; monotherapy and combinations | Define dose, safety, pharmacokinetics, response and durability by tumor type. |
| TARGET-D201 NCT07644559 | June 16, 2026 | Second-line PDAC monotherapy or cetuximab; first-line cetuximab combination cohort | Complete planned enrollment by year-end 2026 and inform Phase 3 design. |
| TARGET-D202 NCT07659782 | July 22, 2026 | Previously treated NSCLC monotherapy, including a brain-metastasis cohort | Test systemic and CNS-relevant activity at the selected dose. |
| TARGET-D203 NCT07659795 | July 28, 2026 | Second-line-plus CRC with cetuximab or panitumumab; frontline cetuximab plus chemotherapy cohort | Measure response after EGFR-pathway suppression and define combination strategy. |
Management guides to complete enrollment in all three Phase 2 studies by year-end 2026, meet FDA on first-line Phase 3 designs in PDAC, CRC and NSCLC by year-end, and enroll the first patients in all three Phase 3 programs during the first half of 2027. This is ambitious for a company of Verastem’s scale.
Execution concentration: three Phase 2 completions, three regulatory design discussions and three Phase 3 starts compress into roughly twelve months. A delay in one program may be manageable; broad slippage would challenge the runway and the credibility of the development plan.
RAMP 205 adds pancreatic-cancer optionality, but the current dataset is hypothesis-generating
RAMP 205 evaluates avutometinib and defactinib with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. At the recommended Phase 2 dose, 29 patients were evaluable as of June 5, 2026; 90% had stage IV disease at diagnosis and median follow-up was 9.8 months.
| Reported measure | Result | Correct interpretation |
|---|---|---|
| Confirmed objective response rate | 52% (15/29) | Encouraging antitumor activity in a small, single-arm combination cohort. |
| 6-month progression-free survival | 68% | Early disease-control signal; median PFS was not the headline presented. |
| 6-month overall survival | 86% | Immature survival estimate at under ten months median follow-up. |
| Tumor shrinkage | 83% | Most patients had some reduction, but shrinkage is not always a confirmed response. |
| On treatment at cut-off | 9 patients | Follow-up and attrition will determine durability. |
No new safety signals were reported. The challenge is attribution: every patient received active chemotherapy, and there was no randomized control. Cross-trial comparisons against historical gemcitabine/nab-paclitaxel or modern regimens can mislead because patient selection, scan schedules and supportive care differ.
Investment role: RAMP 205 is valuable optionality, not the core 2026 underwriting pillar. The program gains material weight only if response durability matures, a controlled development path emerges and funding does not compete excessively with VS-7375 priorities.
Q2 2026 earnings: stronger revenue, a one-time milestone and a high clinical burn rate
| Metric | Q2 2026 | Comparison / interpretation |
|---|---|---|
| Product revenue | $25.078M | Versus $2.137M in the 2025 launch quarter and $18.7M in Q1 2026. |
| COPIKTRA milestone revenue | $15.0M | Triggered when Secura Bio reached $200M cumulative global sales; cash received in July. |
| Total revenue | $40.078M | Not a clean recurring run rate because 37% came from the milestone. |
| Product cost + amortization | $4.041M | $3.762M cost of sales plus $0.279M intangible amortization. |
| R&D expense | $41.338M | Up 67% from $24.786M; TARGET-D expansion is the main strategic cost. |
| SG&A expense | $27.409M | Up 32% from $20.669M as commercial infrastructure expanded. |
| GAAP net loss | $34.673M / $0.35 | Non-GAAP adjusted loss was $30.6M / $0.31; adjustments should not replace cash analysis. |
| H1 operating cash use | $96.025M | Shows the funding burden more clearly than quarterly EPS. |
USD millions · bars share one $41.3M scale · milestone revenue is separated from recurring product revenue
Editorial read: even the strongest launch quarter does not yet cover the cost of the multi-trial development build-out.
At June 30, the balance sheet showed $136.4 million of cash, cash equivalents and investments, $28.9 million of accounts receivable and $2.4 million of inventory. Long-term debt was $73.8 million and total liabilities were $156.5 million. Receivables are now material relative to quarterly product sales, so cash conversion deserves explicit monitoring.
Earnings quality
The $15 million COPIKTRA milestone improved Q2 total revenue and reported loss but is not part of the AVMAPKI FAKZYNJA recurring launch curve. Investors should model product revenue separately from milestone and license income. Product gross profit was attractive before operating expenses, yet the company’s full cost base remains far above gross profit because it is funding several late- and early-stage trials at once.
Transcript limitation
This update uses the company’s 10-Q, earnings release, presentation and official webcast page. No independently verified verbatim earnings transcript was available at the research cut-off, so no management quote is reproduced and no unsupported question-and-answer detail is treated as fact.
Capital and dilution: pro forma liquidity improves, but it is not equivalent to unencumbered cash
Verastem reported $136.4 million in cash and investments at June 30. It presents pro forma liquidity of $201.4 million after adding the $15 million COPIKTRA milestone received in July and an expected $50 million initial Oberland revenue-note tranche scheduled to close on August 28, subject to closing conditions. The $50 million is financing, not operating cash flow.
Composition of the company’s Q2 pro forma presentation · the Oberland tranche is expected financing, not quarter-end cash
June 30 cash + investmentsJuly milestone receiptExpected Oberland financing
Editorial read: 32.3% of the pro forma total comes from post-quarter additions, and most of that addition carries financing obligations.
Existing debt
The company had approximately $73.8 million of long-term debt at quarter-end, related to $75 million of principal notes. The facility carries floating interest and is interest-only through January 2031, subject to its terms.
New revenue notes
The new facility provides up to $75 million: $50 million initially and an optional $25 million before May 15, 2027 if the prior calendar quarter’s worldwide product sales reach at least $40 million.
Revenue participation
The quarterly payment rate is 4.5% of covered revenue. It can decline to 1.75% after December 31, 2031 if the funded amount is fully repaid by the specified test date. Final maturity is June 30, 2033, with possible make-whole obligations.
Why classification matters
Adding financing proceeds to cash without also recognizing the payment burden overstates financial flexibility. The facility reduces near-term equity risk but claims a share of future revenue and can raise the break-even sales level.
Share count bridge
| Instrument | Approximate shares | Economic interpretation |
|---|---|---|
| Common shares outstanding, August 3 | 90.563M | Basic ownership denominator for market-cap arithmetic. |
| November 2025 pre-funded warrants | 3.870M | Near-equity instruments, generally with nominal exercise cost and ownership blockers. |
| April 2025 pre-funded warrants | 5.857M | Near-equity instruments; excluded from the simple common-share headline. |
| Common + pre-funded warrants | ≈ 100.290M | Useful warrant-inclusive denominator before options and other awards. |
At $5.91, basic equity value is approximately $535 million; warrant-inclusive equity value is about $593 million before options. A simplified quarter-end enterprise value using basic equity value, $73.8 million of long-term debt and $136.4 million of cash is approximately $473 million. That calculation excludes revenue-note economics, leases, options, milestones and asset-level probabilities and is not an rNPV.
Going-concern conflict, stated plainly: management says current resources, product revenue and future financing access can fund operations into the second half of 2027. The 10-Q nevertheless says substantial doubt exists for the next twelve months because future product revenue and financing conditions are not considered probable under the applicable accounting standard and the three TARGET-D trials materially increase spending. Both statements are true in their respective frameworks.
Management and governance: commercial delivery must now match clinical ambition
Daniel Paterson has served as chief executive officer and a director since August 2023, president since June 2019 and has been with Verastem since 2012. His tenure spans the company’s restructuring, the LGSOC development strategy, FDA approval and the launch. The senior team also includes Michael Kauffman, M.D., Ph.D., as President of Development; Daniel Calkins as chief financial officer; and Dan Lyons as chief commercial officer.
The central management test has changed. Prior credibility depended on trial execution and regulatory progress. The next phase adds commercial forecasting, working-capital management, disciplined allocation across four development programs and negotiation of financing that does not consume too much future launch value.
Positive execution evidence
FDA approval, five quarters of launch growth, full RAMP 301 enrollment and three rapid Phase 2 starts show that the team can advance multiple operational tracks.
Credibility test ahead
The year-end Phase 2 enrollment target and three Phase 3 starts in H1 2027 are unusually dense. Investors should judge management by dated operational proof, not by the number of programs on a pipeline slide.
The 2026 proxy describes the board as independent except for Paterson, Michael Kauffman and former CEO Brian Stuglik. It also reported two late Form 4 filings for Paterson related to tax withholding and a Rule 10b5-1 sale. Late filing is a governance blemish, but the disclosed transactions do not by themselves establish misconduct or a change in the fundamental thesis.
Ownership, analyst expectations and Stocktwits activity
| Holder / source date | Reported position | Read-through |
|---|---|---|
| RTW Investments · proxy, March 24 | 8.880M / 9.99% | Includes pre-funded warrants subject to ownership blockers; percentage is not directly comparable to basic shares. |
| Deep Track · proxy, March 24 | 9.112M / 9.99% | Also includes pre-funded warrants subject to blockers. |
| BlackRock · amended 13G, July 30 | 6.187M / 7.0% | More recent filing than the proxy ownership table. |
| Vanguard · 13G, July 31 | 4.424M / 5.03% | Passive ownership can change with index and fund flows. |
| Balyasny · proxy, March 24 | 4.767M / 5.33% | Older snapshot; current position may differ. |
| Directors and executives · proxy | 1.725M / 1.94% | Modest direct beneficial ownership relative to specialist funds. |
Analyst consensus is context, not valuation evidence
Public aggregators showed five analysts with an average target near $14.40 around the research cut-off, with visible targets broadly spanning $8 to $18. Provider counts and averages differed, and some targets may predate the Q2 report. Targets embed assumptions about launch growth, clinical probabilities and dilution; they are opinions rather than observable fair value.
Stocktwits: low baseline, earnings spike
A direct count of VSTM messages for the seven complete U.S. Eastern calendar days from July 31 through August 6 found 82 messages, or an average of 11.7 per day and a median of 6. The daily counts were 20, 1, 0, 8, 6, 6 and 41. Excluding the August 6 earnings session, the average was 6.8 per day. The last 24 hours measured early August 7 contained 42 messages.
Direct message count by U.S. Eastern calendar day · July 31–August 6, 2026
Editorial read: the earnings day generated half of the week’s messages; the six-day ex-event baseline averaged only 6.8 per day.
The interpretation is modest day-to-day retail attention with an event-driven spike, not sustained crowding. Message volume does not indicate direction, sentiment quality or future returns. It is useful only as a volatility and attention gauge.
Missing market evidence: a current, verified exchange short-interest and borrow-cost snapshot was not available at the cut-off. This Hub does not infer crowding from stale third-party figures.
Competition: VS-7375 enters a KRAS G12D field that is already moving into pivotal trials
The competitive question is not whether VS-7375 has biological activity. It is whether the program can produce a tumor-specific efficacy, safety and combination profile strong enough to compete with assets that have larger datasets and faster registrational timelines.
Revolution Medicines
Zoldonrasib is a selective RAS(ON) G12D inhibitor. By July 2026, Revolution had begun the randomized Phase 3 RASolute 305 trial with first-line chemotherapy in metastatic G12D pancreatic cancer and had reported combination data in first- and later-line PDAC. That sets a high speed benchmark for Verastem.
VS-7375 differentiation test
Verastem emphasizes dual ON/OFF binding, favorable early tolerability, low rash and combination flexibility. Those attributes become competitively meaningful only if October and later datasets show confirmed responses, durability and dose intensity in comparable settings.
CRC requires combination strategy
EGFR feedback is a known challenge for KRAS inhibition in colorectal cancer. TARGET-D203 is therefore structured around cetuximab or panitumumab combinations. Efficacy must be judged against the added toxicity and logistics of the combination, not against monotherapy alone.
Commercial timing risk
A competitor can establish a treatment standard before VS-7375 completes registration. A later entrant may still succeed through better safety, specific line-of-therapy data, CNS activity or combinations, but the evidence burden rises as the class matures.
Other KRAS G12D programs from large and small biopharma companies remain in clinical development, and program names, owners and status can change quickly. This Hub therefore avoids a decorative long list and focuses on the competitive program with the clearest current Phase 3 evidence.
Timeline: from accelerated approval to a multi-program catalyst stack
May 8, 2025FDA granted accelerated approval to AVMAPKI FAKZYNJA for KRAS-mutated recurrent LGSOC after prior systemic therapy.
December 2025RAMP 301 completed global enrollment, setting up the mid-2027 confirmatory readout.
April 2026Two-year RAMP 201 follow-up and China Breakthrough Therapy designation for GFH375/VS-7375 added durability and regulatory context.
June 16, 2026First patient dosed in TARGET-D201 for pancreatic cancer.
June 17–23, 2026RAMP 205 and VS-7375 clinical updates reported encouraging early activity with important single-arm limitations.
July 22, 2026First patient dosed in TARGET-D202 for previously treated NSCLC.
July 28, 2026First patient dosed in TARGET-D203 for colorectal cancer.
August 6, 2026Q2 results showed $25.1 million product revenue, $136.4 million quarter-end liquidity and increased R&D spending.
August 28, 2026 expectedPlanned closing of the initial $50 million Oberland revenue-note financing, subject to conditions.
October 2026 guidedUpdated VS-7375 clinical data.
Mid-2027 guidedRAMP 301 topline primary-endpoint data.
Catalyst map: financing first, clinical discrimination next
| Window | Event | Why it matters | Evidence class |
|---|---|---|---|
| August 28, 2026 | Expected $50M Oberland closing | Moves pro forma liquidity higher and tests financing conditions. | Contractual target; subject to conditions |
| October 2026 | Updated VS-7375 clinical data | Can convert dose/biomarker evidence into tumor-response and durability evidence. | Company guidance |
| Q3 2026 earnings | AVMAPKI FAKZYNJA launch update | Tests whether Q2 re-acceleration persists and how close sales move to the $40M threshold. | Recurring monitoring event |
| By year-end 2026 | Complete TARGET-D201/202/203 enrollment | Tests operational capacity and supports registrational planning. | Company guidance |
| By year-end 2026 | FDA meetings on first-line Phase 3 designs | Can clarify endpoints, populations and feasibility; meeting occurrence is not agreement. | Company guidance |
| By year-end 2026 | LGSOC franchise self-sustaining target | Would reduce the funding drag of the commercial organization. | Management objective |
| H1 2027 | First patients in three Phase 3 programs | Would confirm a rapid transition from exploratory to registrational development. | Company guidance |
| Mid-2027 | RAMP 301 topline | Confirmatory verdict for the current label and potential KRAS wild-type expansion. | Company guidance; value-defining |
RAMP 205 maturation, Europe/Japan regulatory progress and the Erasca preclinical combination are monitoring items without hard public readout dates at the cut-off. They should not be promoted to dated catalysts until the company provides a defined window.
Bull, base and bear cases—and the observable evidence that changes the view
Bull case
- Product revenue continues to compound, the LGSOC franchise becomes self-sustaining and the $40 million quarterly threshold is reached.
- October VS-7375 data show confirmed responses and early durability at 900 mg across more than one tumor type.
- The company completes Phase 2 enrollment on schedule and enters Phase 3 with FDA-aligned designs.
- RAMP 301 confirms benefit and expands the commercial population beyond KRAS-mutated disease.
- Revenue-linked financing limits equity issuance while commercial cash conversion improves.
Base case
- The launch grows but remains uneven quarter to quarter and does not immediately reach the financing threshold.
- VS-7375 produces credible activity but remains too immature for a definitive competitive ranking.
- One or more TARGET-D timelines slip modestly as the company prioritizes cohorts.
- The Oberland facility extends runway, but ongoing clinical spending preserves dilution risk.
- RAMP 301 remains the dominant mid-2027 binary event.
Bear case
- Q2 included launch timing effects and product revenue decelerates sharply.
- VS-7375 biomarker changes fail to translate into competitive confirmed response or durability.
- Safety worsens at broader exposure or in combinations.
- The three-program build causes cash use to exceed plan, forcing dilutive equity or program cuts.
- RAMP 301 fails to confirm benefit, threatening the existing accelerated approval and expansion case.
Valuation discipline
- Basic market capitalization is about $535 million; warrant-inclusive value is nearer $593 million.
- No target price is supplied because post-earnings consensus, peak-sales assumptions, probability of success and fully loaded program costs are not sufficiently verified.
- The correct action is watchlist / wait for proof, not a rating disguised as a scenario.
Observable falsifiers
- Q3 product revenue falls materially below Q2 without a clear timing explanation, or receivables rise faster than product sales.
- The expected August 28 financing does not close, closes on materially different economics, or the company removes it from pro forma liquidity.
- October data emphasize biomarkers without providing interpretable confirmed response, dose, safety and follow-up information.
- Year-end Phase 2 enrollment guidance is withdrawn across multiple programs.
- Management’s runway moves earlier than mid-2027 or the company raises equity at a distressed price.
- RAMP 301 timing slips materially or the trial fails its confirmatory objective.
Bottom line: VSTM now has more than one way to win, but it also has more than one way to consume capital. The launch has created real value and reduced pure binary risk. October VS-7375 data can validate a second franchise; RAMP 301 can protect and expand the first. Until commercial cash conversion and pivotal probabilities become clearer, the stock belongs on a disciplined catalyst watchlist rather than in an unsupported target-price framework.
Primary sources and research notes
- Verastem Oncology Form 10-Q for the quarter ended June 30, 2026 — financials, cash flow, share count, financing, going-concern language and clinical updates.
- Q2 2026 financial results and business update — August 6, 2026.
- Q2 2026 earnings presentation.
- Official Q2 2026 earnings webcast page.
- FDA accelerated-approval notice for avutometinib plus defactinib — May 8, 2025.
- VS-7375 clinical activity, safety and pharmacokinetics update — June 23, 2026.
- RAMP 205 updated results — June 17, 2026.
- TARGET-D201 first patient — June 16, 2026.
- TARGET-D202 first patient — July 22, 2026.
- TARGET-D203 first patient — July 28, 2026.
- 2026 proxy statement — management, governance and March ownership snapshot.
- BlackRock amended Schedule 13G — July 30, 2026; Vanguard Schedule 13G — July 31, 2026.
- Revolution Medicines zoldonrasib combination data and Phase 3 context — July 2, 2026.
Market-data note: the price snapshot uses the August 6, 2026 full-session close of $5.91 from the connected market-data feed. Basic market capitalization is arithmetic derived from that price and 90,563,441 common shares reported as of August 3. The warrant-inclusive figure adds 9.727 million disclosed pre-funded warrants and excludes options. Analyst targets are third-party aggregated opinions and were not used to set a fair value.
Update log: rebuilt August 7, 2026 after Q2 results; replaced the earlier article-format page with the full advanced Stock Hub architecture; added full-size chart, launch history, RAMP 301, VS-7375/TARGET-D, RAMP 205, Q2 financials, capital structure, ownership, Stocktwits activity, competition, scenarios, related coverage and primary-source register.
Follow new Stock Hub updates
Join the English Merlintrader channel for biotech catalysts, earnings updates and newly refreshed company hubs.
Educational disclaimer: This Stock Hub is independent editorial research for educational and informational purposes only. It is not investment advice, a recommendation, an offer or a solicitation to buy or sell securities. Biotechnology shares can be extremely volatile and may lose most or all of their value following clinical, regulatory, financing or commercial setbacks. Company guidance, market data and trial timelines can change after the research cut-off. Readers should verify current filings and primary sources and make decisions consistent with their own objectives and risk tolerance.